menu
    • menu
    [{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2-neutralizing antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Memo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Northway Biotechpharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"MTX-COVAB","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Memo Therapeutics AG","highestDevelopmentStatusID":"2","companyTruncated":"Memo Therapeutics \/ Memo Therapeutics AG"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Swisscanto","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"MTX-COVAB","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Swisscanto","highestDevelopmentStatusID":"8","companyTruncated":"Memo Therapeutics \/ Swisscanto"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MTX-COVAB","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Memo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"MTX-COVAB","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Serum Institute of India","highestDevelopmentStatusID":"4","companyTruncated":"Memo Therapeutics \/ Serum Institute of India"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Swiss Federal Funding","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"Covab 36","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Memo Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Memo Therapeutics \/ Swiss Federal Funding","highestDevelopmentStatusID":"4","companyTruncated":"Memo Therapeutics \/ Swiss Federal Funding"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Swisscanto","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Series B Financing","leadProduct":"MTX-005","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Memo Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Swisscanto","highestDevelopmentStatusID":"6","companyTruncated":"Memo Therapeutics \/ Swisscanto"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MTX-005","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Memo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Memo Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BKV Neutralising Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BKV Neutralising Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BKV Neutralising Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Series C Financing","leadProduct":"BKV Neutralising Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Ysios Capital","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Ysios Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Memo Therapeutics

    Menu

    Memo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BKV Neutralising Antibody

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Ysios Capital

                            Deal Size : $49.4 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Memo Therapeutics Increases Series C Financing to CHF 45 Million

                            Details : The new funding will bolster clinical advancement of MTx’s lead asset, AntiBKV, expanding the Phase II trial to become the largest BK viremia therapeutic study in kidney transplant recipients.

                            Brand Name : AntiBKV

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 07, 2024

                            Lead Product(s) : BKV Neutralising Antibody

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Ysios Capital

                            Deal Size : $49.4 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BKV Neutralising Antibody

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Memo Therapeutics AG Starts U.S. Pivotal Phase II/III Clinical Trial with AntiBKV for Treatment of BKV Infecti...

                            Details : AntiBKV is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection.

                            Brand Name : AntiBKV

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 22, 2023

                            Lead Product(s) : BKV Neutralising Antibody

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BKV Neutralising Antibody

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Memo Therapeutics AG Receives FDA Fast Track Designation for AntiBKV as Treatment of BKV Infection in Renal Tr...

                            Details : AntiBKV is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection.

                            Brand Name : AntiBKV

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 02, 2023

                            Lead Product(s) : BKV Neutralising Antibody

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BKV Neutralising Antibody

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Memo Therapeutics AG Announces Positive Phase I Data with AntiBKV for Treatment of BKV Infection in Renal Tran...

                            Details : AntiBKV is a neutralizing antibody which has been indicated for the treatment of BK virus infections and prevention of BK virus associated complications in kidney transplant recipients.

                            Brand Name : AntiBKV

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 24, 2023

                            Lead Product(s) : BKV Neutralising Antibody

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Ono Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets

                            Details : Under the terms of the agreement, MTx will leverage its best-in-class microfluidic single-cell molecular cloning and screening technologies to discover antibodies for immuno-oncology targets.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 01, 2022

                            Lead Product(s) : Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Ono Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTX-005

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Memo Therapeutics AG Initiates Phase 1 Clinical Study of MTX-005 Against BK Virus Infection

                            Details : MTX-005 is a therapeutic antibody candidate that was identified through the screening of a vast number of kidney transplant patients infected with BK virus to find those few with an eradicating antibody response against the virus.

                            Brand Name : MTX-005

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 31, 2022

                            Lead Product(s) : MTX-005

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTX-005

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Swisscanto

                            Deal Size : $40.2 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Memo Therapeutics AG Closes Series B Financing at CHF37 Million Following Oversubscribed CHF23 Million Extensi...

                            Details : The proceeds will be used to advance clinical development of its best- and first-in-class neutralizing antibody, MTX-005, targeting BK virus infection in renal transplant patients through Phase 2 clinical development.

                            Brand Name : MTX-005

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 16, 2022

                            Lead Product(s) : MTX-005

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Swisscanto

                            Deal Size : $40.2 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Covab 36

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Swiss Federal Funding

                            Deal Size : $11.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Memo Therapeutics AG to Receive CHF 10.5 Million from Swiss Federal Funding Programme to Clinically Develop SA...

                            Details : The project also includes the ability to rapidly develop a combination antibody partner for COVAB 36 targeted against emerging variants through an ultra-fast update process based on Memo Therapeutic AG’s leading antibody discovery platform.

                            Brand Name : Covab 36

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 13, 2021

                            Lead Product(s) : Covab 36

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Swiss Federal Funding

                            Deal Size : $11.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTX-COVAB

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Serum Institute of India

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant

                            Details : MTX-COVAB, human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7).

                            Brand Name : MTX-COVAB

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 17, 2021

                            Lead Product(s) : MTX-COVAB

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Serum Institute of India

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Memo Therapeutics

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTX-COVAB

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Memo Therapeutics's Antibody Against Sars-Cov-2 Shows Potent Therapeutic and Prophylactic Activity in Advanced...

                            Details : In the hamster challenge model, even low MTX-COVAB (5 mg/kg preventive; 10 mg/kg therapeutic) protected against weight loss, a key indicator of disease severity.

                            Brand Name : MTX-COVAB

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 03, 2020

                            Lead Product(s) : MTX-COVAB

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth